An 18 Month, Open Label Study of the Tolerability and Efficacy of a Combination of Doxycycline and Tauroursodeoxycholic Acid (TUDCA) in Patients With Transthyretin Amyloid Cardiomyopathy

Trial Profile

An 18 Month, Open Label Study of the Tolerability and Efficacy of a Combination of Doxycycline and Tauroursodeoxycholic Acid (TUDCA) in Patients With Transthyretin Amyloid Cardiomyopathy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Doxycycline (Primary) ; Tauroursodeoxycholic acid (Primary)
  • Indications Amyloidosis; Cardiomyopathies
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 11 Jan 2016 Planned primary completion date changed from 1 Sep 2015 to 1 Jul 2016 as reported by ClinicalTrials gov record.
    • 27 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top